Evidence map›Paper›PMID 39336931›Full record

ReviewJournal of clinical medicine2024

Screening Strategies to Improve Early Diagnosis in Endometrial Cancer.

Silvia Cabrera, Irene de la Calle, Sonia Baulies, Antonio Gil-Moreno, Eva Colas

Abstract readReview
In one paragraph

Review in Journal of clinical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Silvia CabreraGynecologic Oncology Unit, Department of Gynecology and Obstetrics, Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Spain.ORCID 0000-0002-3164-6686
Irene de la CalleResearch Group in Gynecology, Vall d'Hebron Institut de Recerca, 08035 Barcelona, Spain.
Sonia BauliesFundación Santiago Dexeus Font, Gynecology, Obstetrics and Reproductive Medicine Department, Dexeus Mujer, 08028 Barcelona, Spain.
Antonio Gil-MorenoResearch Group in Gynecology, Vall d'Hebron Institut de Recerca, 08035 Barcelona, Spain.ORCID 0000-0003-1106-5590
Eva ColasResearch Group in Gynecology, Vall d'Hebron Institut de Recerca, 08035 Barcelona, Spain.ORCID 0000-0003-0302-4828

Funding

Centro de Investigación Biomédica en Red de Cáncer CB16/12/00328Departament de Recerca i Universitats SGR 2021 01157European Commission PERME212443COLAInstituto de Salud Carlos III PI20/00644, PI23/01470, IFI19/00029Ministerio de Ciencia, Tecnología e Innovación CPP2022-009817
6 · The paper itself

Abstract

Endometrial cancer is the most common gynecological malignancy in high-income countries and the sixth most common cancer in women. Overall incidence has risen in the last few decades as a consequence of the increase in the prevalence of its risk factors, mainly obesity and the aging of the population, and although diagnoses have increased across all age groups, the incidence rates have doubled in women under the age of 40 years. The survival rates of endometrial cancer are highly dependent on its stage at diagnosis, bringing to the fore the importance of early diagnosis. The aim of a screening strategy in this type of tumor should be to detect the disease in the pre-invasive or early stage (before developing myometrial invasion), which would improve cure rates, reduce the morbidity associated with aggressive treatment and offer uterus-sparing management options for younger women. The ideal screening tool in this scenario would be a minimally invasive, inexpensive and easy-to-perform test or auto-test, which could be implemented in a routine gynecologic checkup of patients at-risk or in the general adult population. In this comprehensive review, we aim to define the populations at higher risk of developing endometrial cancer, to assess the performance of current diagnostic tools when used in a screening setting and to discuss the accuracy of new molecular screening strategies.

Indexed as

diagnosisendometrial cancerhigh-risk populationscreening

Identifiers

PMID39336931
PMCPMC11432712

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.